The Board of AnteoTech Limited announced the appointment of Mr. David Radford as Managing Director and Chief Executive Officer (CEO), effective from 4 October 2022. The Board's search process commenced in March, following the resignation of incumbent CEO Mr. Derek Thomson, who agreed to serve out the six-month notice period in accordance with his contract. Mr. Radford is an internationally experienced CEO and Company Director with a track record of identifying and delivering profitable growth across a range of industries and geographies.

He has direct experience in coordinating international teams, executing business turnarounds, product development and product launches, and operational initiatives to drive material growth in revenue and profits. Most recently, he served as CEO of Australian medical device company AllVascular, which develops and sells patented drug delivery technology with regulatory approval in Europe (CE Mark) and Australia (TGA). Mr. Radford has built his career through senior executive roles at blue-chip listed companies, ASX- listed small caps and private equity-owned businesses including Recall Asia (then part of Brambles Australia), General Electric and Nanosonics Limited.

With experience across public capital markets, private companies and working directly with private equity investors, Mr. Radford has a wealth of experience managing and communicating with multiple stakeholders. He holds an MBA from the Australian Graduate School of Management, a Bachelor of Science (Biological Sciences) from Bristol Polytechnic and is a Graduate of the Australian Institute of Company Directors.